Transfusion Trigger After Operations in High Cardiac Risk Patients

Myocardial Infarction Clinical Trial

— TOP  

Official title:

CSP #599 - Transfusion Trigger After Operations in High Cardiac Risk Patients (TOP)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03229941
• Other study ID #: 599
• Status: Completed
• Phase: N/A
• Start date: February 5, 2018
• Est. completion date: March 2, 2024

Study information

• Verified date: March 2024
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of the proposed study is to determine whether a liberal transfusion strategy (transfusion trigger at Hb < 10 gm/dl) in Veterans at high cardiac risk who undergo major open vascular and general surgery operations is associated with decreased risk of adverse postoperative outcomes compared to a restrictive transfusion strategy (transfusion trigger at Hb < 7 gm/dl).

Description:

Background: Despite the need for clinically appropriate use of blood products in the postoperative setting, blood transfusion practices are empiric and variable. In the absence of a physiologic test that can effectively guide transfusion-related decisions after an operative intervention, hemoglobin-based transfusion triggers have been suggested as clinical tools. Traditionally, clinicians have transfused patients to maintain hemoglobin (Hb) above a minimum (typically 10 gm/dl) level, in order to prevent adverse cardiac events and death. Recent randomized trials, however, have shown that restrictive transfusion policies (transfusion when Hb falls below 8 gm/dl or even lower) are well tolerated by specific patient populations. Furthermore, these trials have demonstrated that in some patient subsets reduced transfusion is associated with reduction in postoperative complications and death. Thus, guidelines have been developed emphasizing the need for a restrictive transfusion strategy in most stable hospitalized patients.

Despite the emerging enthusiasm with respect to the safety of restrictive transfusion strategies, high quality evidence on the value of such an approach in patients at high risk for postoperative adverse cardiac events remains scarce. This is a serious limitation of the current literature, as ischemic heart disease (IHD) is highly prevalent and represents the leading cause of mortality in this country, accounting for the death of one American every minute. Furthermore, there is evidence from small trials and secondary analyses that in this subset of patients withholding transfusion when Hb falls below 10 gm/dl increases the risk of death or myocardial infarction, suggesting that widespread use of restrictive transfusion policies may actually result in patient harm. This uncertainty on transfusion thresholds in high cardiac risk patients has created a knowledge gap that requires urgent attention. IHD is highly prevalent in patients with peripheral arterial disease (PAD), and myocardial infarction represents the leading cause of postoperative mortality in patients undergoing PAD-related surgical interventions. Furthermore, a substantial proportion of patients undergoing Vascular and General Surgery operations have history of prior IHD, making this patient population an ideal high cardiac risk group in which to analyze the effect of transfusion strategies. In order to address the knowledge gap of postoperative transfusion thresholds in patients at high risk for postoperative adverse cardiac events, the investigators propose the current study under the hypothesis that transfusion strategy will affect important postoperative outcomes after major surgical interventions in high cardiac risk patients.

Objectives: The goal of the proposed study is to determine whether a liberal postoperative transfusion strategy (transfusion trigger at Hb<10gm/dl) in patients at high risk for postoperative adverse cardiac events will reduce the risk of adverse postoperative outcomes after major vascular and general surgery operative interventions. The primary end point is the composite rate of all-cause mortality, acute myocardial infarction (MI), coronary revascularization, stroke, or acute renal failure within 90 days from the time of randomization. The secondary end points are rates of postoperative infectious complications (wound infections, pneumonia, and sepsis), and postoperative cardiac complications (new cardiac arrhythmias, congestive heart failure exacerbation, and cardiac arrest) at 90 days post-randomization; the composite rate of all-cause mortality, MI, coronary revascularization, stroke, or acute renal failure, within 30 days from the time of randomization; the length of hospital stay; and all-cause mortality up to one year after randomization.

Design: CSP #599 - TOP study is a randomized, intent-to-treat, two-arm, parallel design, single blind, multicenter trial. Vascular and General Surgery programs at Veterans Affairs Medical Centers with expertise in performing the operations of interest will be invited to participate and participants will be screened for enrollment using established inclusion/exclusion criteria. Enrolled participants will be randomized to one of the two arms; liberal (transfusion trigger at Hb < 10gm/dl) or restrictive (transfusion trigger at Hb < 7gm/dl). Consent for the study will be obtained prior to the index surgical intervention. Randomization will be performed postoperatively after the patient has a confirmed Hb < 10gm/dl. Assessments will be collected pre/post-operatively and at discharge, or at 30 days after randomization if the patient is still hospitalized. Follow up forms will be filled out during a clinic visit after the 30th and 90th post-randomization day. Patients who cannot present to the clinic will have a phone call for follow up. One year post-randomization mortality will be ascertained using electronic medical records, phone follow-up, and search of the national death index.

Sample Size and Study Duration: This study will randomize 1520 participants undergoing major vascular and general operations at 15 VA medical centers with expertise in Vascular and General surgical procedures. Assuming a recruitment rate of 3 participants per site per month, total recruitment will take approximately four years to complete. The duration of the study will be five years with four year recruitment, three months active follow up, and nine months passive follow up which will be performed by the Chairman's office in order to collect 1-year post-randomization data on all-cause mortality.

Study Population: The study will include a) patients who undergo open (non-endovascular) PAD

• related operations, and b) patients who undergo selected major Vascular and General Surgery operations and have prior history of PAD or IHD. Vascular Surgery operations examined will include, but not be limited to, PAD-related: aortobifemoral or aortobiiliac bypass, open abdominal aortic aneurysm repair with simultaneous repair of aortoiliac occlusive disease, visceral bypass, iliofemoral bypass, femoral bypass or endarterectomy, infrainguinal bypass, supra-aortic trunk bypass or endarterectomy, carotid endarterectomy, and major lower extremity amputations (transfemoral, through the knee, or transtibial); Other vascular surgeries: open aneurysm repair (including but not limited to carotid, subclavian, abdominal aortic, iliac, femoral, or popliteal aneurysms); and complex endovascular aneurysm repair (defined as fenestrated endograft, or endograft with need for iliac conduit, or endovascular aneurysm repair with simultaneous femoral artery reconstruction or bypass). General Surgery operations examined will include open cholecystectomy or other complex biliary reconstruction (such as open common bile duct exploration for stones, reconstruction as part of oncologic operations such as palliative pancreatic cancer procedures) , small bowel resection, pancreatectomy, colon resection, rectal resection, splenectomy, transhiatal esophagectomy, liver resection, and open ventral hernia repair. Patients will be included in the study if their postoperative Hb falls below 10gm/dl within 15 days after surgery. Intervention: Liberal transfusion strategy is the conventional transfusion method for the surgical procedures the investigators will include in the study, and is defined as transfusion when the postoperative Hb drops below 10gm/dl, with a goal to maintain Hb above 10 gm/dl. Restrictive transfusion strategy will be defined as transfusion when the postoperative Hb drops below 7gm/dl with goal to maintain Hb above 7 gm/dl.

Significance: The proposed CSP# 599 study is uniquely positioned to address the knowledge gap of postoperative transfusion thresholds in high cardiac risk patients undergoing major surgical interventions, who are currently transfused based on data from patient populations with different risk profile. The study will include patients with high IHD burden, a population that should be the most likely to benefit from a liberal transfusion strategy and CSP#599 will examine this hypothesis directly. Conversely, if the proposed trial demonstrates that this high cardiac risk patient population can tolerate restrictive transfusion well, then the results will be easy to generalize to other patient populations and the question of transfusion thresholds will be definitively addressed. Thus, the investigators believe that regardless of outcome this trial will have significant clinical and policy implications, and will substantially impact the VA and national transfusion-related guidelines.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3012
• Est. completion date: March 2, 2024
• Est. primary completion date: June 2, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and females older than 18 years of age who have postoperative Hb < 10gm/dl within 15 days after the index operation

• Patients who undergo an operation in either one of the three following categories:

• Veterans who undergo PAD - related operations including but not limited to the following:

• aortobifemoral or aortobiiliac bypass

• open abdominal aortic aneurysm repair with simultaneous repair of aortoiliac occlusive disease

• visceral bypass

• iliofemoral bypass

• femoral bypass or endarterectomy

• infrainguinal bypass

• thromboembolectomy

• supra-aortic trunk bypass or endarterectomy

• carotid endarterectomy

• major lower extremity amputations (transfemoral, through the knee, or transtibial)

• Veterans with past medical history of ischemic stroke or IHD or PAD who undergo the following general surgery procedures, defined as:

• known prior MI

• ECG findings consistent with prior MI

• prior percutaneous coronary intervention

• prior coronary artery bypass surgery

• history of angina for which the patient is currently receiving treatment

• stress test indicating myocardial ischemia

• who undergo the following General Surgery operations:

• Open cholecystectomy or other complex biliary reconstruction

• such as open common bile duct exploration for stones

• reconstruction as part of oncologic operations such as palliative pancreatic cancer procedures)

• small bowel resection

• pancreatectomy

• colon resection

• rectal resection

• splenectomy

• transhiatal esophagectomy

• liver resection

• gastric resection

• open ventral hernia repair

• Colostomies (reversals and takedowns)

• Intestinal anastomosis takedowns and revisions

• Gastric bypass

• Adrenalectomies

• Major diaphragmatic hiatal hernia repairs

• Veterans with past medical history of ischemic stroke or IHD or PAD who undergo the following Vascular Surgery operations:

• Open aneurysm repair, including but not limited to:

• carotid

• subclavian

• abdominal aortic

• iliac

• femoral

• popliteal aneurysms

• and complex endovascular aneurysm repair, defined as:

• fenestrated endograft

• or endograft with need for iliac conduit

• or endovascular aneurysm repair with simultaneous femoral artery reconstruction or bypass

• Subclavian/vertebral bypasses and transpositions

• Patients undergoing the above procedures will be included in the study regardless of their preoperative Hb level, and regardless of preoperative or intraoperative transfusion they might have received.

Exclusion Criteria:

• Veteran unable to consent

• Veteran unwilling to follow protocol (such as Jehovah's witnesses)

• Veteran with known history of hereditary anemias such as Thalassemia or Sickle cell disease

• Veteran with known history of hereditary bleeding disorders, such as factor VIII or factor IX deficiency

• Veteran with prior history of adverse reaction to blood administration, such as fever, rash, or hemolysis

• Veteran does not speak or understand English

• Veteran hemodynamically unstable or in cardiogenic shock for >48 hours after the index procedure

• Veteran participating in another interventional trial whose objective is to evaluate the effect of transfusion on outcomes

• Pregnancy in female Veterans

• Veteran is a prisoner or in custody of law enforcement

• Prior randomization in the CSP#599

• Patients who are known to have tested positive for COVID-19 and have not recovered prior to consent will not be consented. Any participant who is known to have a positive COVID-19 test during the screening process and has not recovered will be excluded prior to randomization.

Related Conditions & MeSH terms

• Acute Kidney Injury
• Acute Renal Failure
• Coronary Revascularization
• Infarction
• Myocardial Infarction

Intervention

Procedure:
• Blood Transfusion
Blood Transfusion

Locations

Country	Name	City	State
United States	Asheville VA Medical Center, Asheville, NC	Asheville	North Carolina
United States	VA Western New York Healthcare System, Buffalo, NY	Buffalo	New York
United States	Louis Stokes VA Medical Center, Cleveland, OH	Cleveland	Ohio
United States	VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX	Dallas	Texas
United States	North Florida/South Georgia Veterans Health System, Gainesville, FL	Gainesville	Florida
United States	Michael E. DeBakey VA Medical Center, Houston, TX	Houston	Texas
United States	Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR	Little Rock	Arkansas
United States	VA Loma Linda Healthcare System, Loma Linda, CA	Loma Linda	California
United States	VA Long Beach Healthcare System, Long Beach, CA	Long Beach	California
United States	Minneapolis VA Health Care System, Minneapolis, MN	Minneapolis	Minnesota
United States	VA Palo Alto Health Care System, Palo Alto, CA	Palo Alto	California
United States	VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA	Pittsburgh	Pennsylvania
United States	VA Portland Health Care System, Portland, OR	Portland	Oregon
United States	San Francisco VA Medical Center, San Francisco, CA	San Francisco	California
United States	VA Puget Sound Health Care System Seattle Division, Seattle, WA	Seattle	Washington
United States	James A. Haley Veterans' Hospital, Tampa, FL	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The investigators will examine individual rates of the outcomes that consist of individual components of the primary endpoint.	All cause postoperative mortality, Postoperative MI, Postoperative coronary revascularization, Postoperative stroke,Postoperative acute renal failure	90 days after randomization
Primary	A composite endpoint of all-cause post-randomization mortality, myocardial infarction (MI), coronary revascularization, acute renal failure, or post-randomization ischemic stroke up to 90 days after randomization.	MI will be defined using the Third Universal Definition of Myocardial Infarction. Acute renal failure will be defined as Acute Kidney Injury stage III according to RIFLE criteria. Baseline creatinine will be considered the creatinine upon admission prior to the index operation. The above urine output criteria will be only used for patients who are in the ICU and have precise monitoring of their urinary output. For patients on the surgical floor only serum creatinine changes will be used for assessment of this endpoint. Coronary revascularization will be defined as a coronary artery bypass graft, or percutaneous coronary intervention (either angioplasty or stenting). Stroke will be defined as new unilateral neurological deficit that lasts for more than 24 hours, and is confirmed by a brain imaging modality (computed tomography or magnetic resonance imaging study) demonstrating new brain infarct.	90 days after randomization
Secondary	A composite endpoint of postoperative infectious complications at 90 days post-randomization: Infectious complications will include wound infections, pneumonia, and sepsis.	Wound infection will be defined according to the Centers for Disease Control and Prevention (CDC) guidelines as a) positive wound culture, or b) drainage of pus from a wound, or c) suspicion of wound infection that was drained operatively.; Pneumonia will be defined according to the CDC definition as chest radiograph with new or progressive infiltrate, consolidation, cavitation, or pleural effusion and any of the following: new onset of purulent sputum or change in character of sputum, or organism isolated from blood culture, trans-tracheal aspirate, bronchial brushings, or biopsy.; Sepsis will be defined as a combination of two of the following systemic inflammatory response syndrome (SIRS) criteria, plus suspected or present source of infection. SIRS criteria will include the following: temperature greater than 38C, heart rate greater than 90 beats/min, WBC > 12,000 or < 4,000, or > 10% bands.	90 days after randomization
Secondary	A composite endpoint of cardiac complications (other than MI) at 90 days post-randomization: Cardiac complications will include new cardiac arrhythmias that necessitate new treatment, new or worsening congestive heart failure (CHF), and cardiac arrest no	The diagnosis of cardiac arrhythmias will be based on EKG findings. Only arrhythmias that result in initiation of new treatment regimen (to include medications, implantable devices, or surgical intervention) during hospitalization will be recorded.; CHF will require at least one of the following symptoms or signs new or worsening: dyspnea at rest, orthopnea, or paroxysmal nocturnal dyspnea and radiological evidence of heart failure or worsening heart failure and increase/initiation of established treatment.; Cardiac arrest will be defined as the cessation of cardiac pump function activity that results in loss of consciousness and absence of circulating blood flow as evidenced by absent carotid pulse. Only episodes of cardiac arrest that are reversed will be collected under this endpoint. If they are not reversed the event will be categorized as death.	90 days after randomization
Secondary	All-cause mortality at 1 year after randomization.	The investigators will determine vital status by telephoning participants after hospital discharge, by searching the electronic medical record and the National Death Index.	12 months after randomization
Secondary	A composite endpoint of all-cause mortality,	MI, coronary revascularization, acute renal failure, or postoperative ischemic stroke.	30 days after randomization
Secondary	Length of hospital stay.	Length of hospital stay	At hospital discharge, up to 1 year